Previous 10 | Next 10 |
Fiscal 2021 revenue increased 12% year-over-year to $46.5 million Software revenue increased 28% year-over-year to $27.7 million Fiscal 2022 financial outlook for total revenue of $51 million to $53 million, reflecting 10% to 15% year-over-year growth ...
Free access to Simulations Plus software for accredited universities will accelerate learning and educational pursuits Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, t...
The after-effects of pandemic-era policies will be with us for some time - with many supply chains and labor markets still experiencing significant disruption. Everyone likes to complain about drug prices, but here is the unpleasant truth: discovering new drugs is expensive and risky....
Board of Directors announces quarterly dividend of $0.06 per share Simulations Plus, Inc. (Nasdaq: SLP) announced today that the Company’s Board of Directors has declared a cash dividend of $0.06 per share of the Company’s common stock, payable on November ...
Conference Call to be on Monday, October 25, 2021, at 5:00 PM ET Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its fourth quarter and full year financial results for fiscal year 2021, ended August 31, 2021, after the close of the financial mar...
The following slide deck was published by Simulations Plus, Inc. in conjunction with this event. For further details see: Simulations Plus (SLP) Investor Presentation - Slideshow
Improvements to the GastroPlus ® platform will increase its impact in driving research and regulatory decisions on dermatological products Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, b...
New capabilities further solidify ADMET Predictor’s position as the preferred platform for ADMET modeling and AI-driven compound optimization Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, ...
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that chief executive officer Shawn O’Connor will be presenting at two upcoming investor conferences: BofA Securi...
The 23 businesses comprise 99% of the portfolio with the other 1% in cash, and the average total return over the Dow average for the 68-month test period is 56.91%. The portfolio's objective is to create a balanced portfolio that is not income, not dividend growth, not bottom fishing,...
News, Short Squeeze, Breakout and More Instantly...
Objective to define best practices for the use of novel PBK modeling strategies to support animal-free safety assessment of new chemicals Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance an...
Total revenue of $18.5 million and diluted earnings per share (EPS) of $0.15 Maintains full-year revenue guidance of $69 to $72 million and updates EPS guidance Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulati...
2024-06-24 16:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...